- Home
- / Lukas Biomedical
Lukas Biomedical
Stock Price
NT$30.3
2024-10-29
Market Capitalization
NT$1.3 B
2024-10-29
Revenue
NT$189.8 M
FY, 2024
Lukas Biomedical Summary
Company Summary
- Overview
- Lukas Biomedical (路迦生醫股份有限公司) is a company that specializes in the research and the development of immunotherapy therapy for cancer treatment. It develops immune and stem cell medical technologies for regenerative medicines.
- Type
- Public
- Status
- Active
- Founded
- 2013
- Website
- https://lukas-bio.com.tw
- Cybersecurity rating
Table of Contents
Lukas Biomedical Financials
Summary Financials
- Revenue (H1, 2025)
- NT$87.9M
- Gross profit (H1, 2025)
- NT$64.6M
- Net income (H1, 2025)
- (NT$42.5M)
- Cash (H1, 2025)
- NT$40.3M
- EBIT (H1, 2025)
- (NT$41.0M)
- Enterprise value
- $1.4B
Footer menu
Product
- Intelligence Suite
- Supplier Intelligence Platform
- Craft Intelligence Portal
- Craft API
- Craft for Teams
- Supplier Intelligence Platform
- Craft Alerts
- Craft N-Tier Mapping
- Craft Risk Hub
- Chrome extension
Resources
© Craft.co 2026